These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 23172909)

  • 1. Ataxin-2 interacts with FUS and intermediate-length polyglutamine expansions enhance FUS-related pathology in amyotrophic lateral sclerosis.
    Farg MA; Soo KY; Warraich ST; Sundaramoorthy V; Blair IP; Atkin JD
    Hum Mol Genet; 2013 Feb; 22(4):717-28. PubMed ID: 23172909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS.
    Soo KY; Halloran M; Sundaramoorthy V; Parakh S; Toth RP; Southam KA; McLean CA; Lock P; King A; Farg MA; Atkin JD
    Acta Neuropathol; 2015 Nov; 130(5):679-97. PubMed ID: 26298469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.
    Hart MP; Brettschneider J; Lee VM; Trojanowski JQ; Gitler AD
    Acta Neuropathol; 2012 Aug; 124(2):221-30. PubMed ID: 22526021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Conjoint pathological cascades mediated by RNA-binding proteins, TDP-43, FUS and ataxin-2].
    Ito D
    Rinsho Shinkeigaku; 2012; 52(11):1221-3. PubMed ID: 23196570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.
    Lee T; Li YR; Ingre C; Weber M; Grehl T; Gredal O; de Carvalho M; Meyer T; Tysnes OB; Auburger G; Gispert S; Bonini NM; Andersen PM; Gitler AD
    Hum Mol Genet; 2011 May; 20(9):1697-700. PubMed ID: 21292779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
    Ito D; Suzuki N
    Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.
    Hart MP; Gitler AD
    J Neurosci; 2012 Jul; 32(27):9133-42. PubMed ID: 22764223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein disulphide isomerase (PDI) is protective against amyotrophic lateral sclerosis (ALS)-related mutant Fused in Sarcoma (FUS) in in vitro models.
    Parakh S; Perri ER; Vidal M; Sultana J; Shadfar S; Mehta P; Konopka A; Thomas CJ; Spencer DM; Atkin JD
    Sci Rep; 2021 Sep; 11(1):17557. PubMed ID: 34475430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant FUS induces endoplasmic reticulum stress in amyotrophic lateral sclerosis and interacts with protein disulfide-isomerase.
    Farg MA; Soo KY; Walker AK; Pham H; Orian J; Horne MK; Warraich ST; Williams KL; Blair IP; Atkin JD
    Neurobiol Aging; 2012 Dec; 33(12):2855-68. PubMed ID: 22459602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative proteomics identifies proteins that resist translational repression and become dysregulated in ALS-FUS.
    Baron DM; Matheny T; Lin YC; Leszyk JD; Kenna K; Gall KV; Santos DP; Tischbein M; Funes S; Hayward LJ; Kiskinis E; Landers JE; Parker R; Shaffer SA; Bosco DA
    Hum Mol Genet; 2019 Jul; 28(13):2143-2160. PubMed ID: 30806671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
    Daigle JG; Lanson NA; Smith RB; Casci I; Maltare A; Monaghan J; Nichols CD; Kryndushkin D; Shewmaker F; Pandey UB
    Hum Mol Genet; 2013 Mar; 22(6):1193-205. PubMed ID: 23257289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions.
    Highley JR; Lorente Pons A; Cooper-Knock J; Wharton SB; Ince PG; Shaw PJ; Wood J; Kirby J
    Neuropathol Appl Neurobiol; 2016 Jun; 42(4):377-89. PubMed ID: 26095883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taking a risk: a therapeutic focus on ataxin-2 in amyotrophic lateral sclerosis?
    van den Heuvel DM; Harschnitz O; van den Berg LH; Pasterkamp RJ
    Trends Mol Med; 2014 Jan; 20(1):25-35. PubMed ID: 24140266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Directly converted patient-specific induced neurons mirror the neuropathology of FUS with disrupted nuclear localization in amyotrophic lateral sclerosis.
    Lim SM; Choi WJ; Oh KW; Xue Y; Choi JY; Kim SH; Nahm M; Kim YE; Lee J; Noh MY; Lee S; Hwang S; Ki CS; Fu XD; Kim SH
    Mol Neurodegener; 2016 Jan; 11():8. PubMed ID: 26795035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pur-alpha regulates cytoplasmic stress granule dynamics and ameliorates FUS toxicity.
    Daigle JG; Krishnamurthy K; Ramesh N; Casci I; Monaghan J; McAvoy K; Godfrey EW; Daniel DC; Johnson EM; Monahan Z; Shewmaker F; Pasinelli P; Pandey UB
    Acta Neuropathol; 2016 Apr; 131(4):605-20. PubMed ID: 26728149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS).
    Nihei Y; Ito D; Suzuki N
    J Biol Chem; 2012 Nov; 287(49):41310-23. PubMed ID: 23048034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stepwise acquirement of hallmark neuropathology in FUS-ALS iPSC models depends on mutation type and neuronal aging.
    Japtok J; Lojewski X; Naumann M; Klingenstein M; Reinhardt P; Sterneckert J; Putz S; Demestre M; Boeckers TM; Ludolph AC; Liebau S; Storch A; Hermann A
    Neurobiol Dis; 2015 Oct; 82():420-429. PubMed ID: 26253605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72.
    McGurk L; Lee VM; Trojanowksi JQ; Van Deerlin VM; Lee EB; Bonini NM
    J Neuropathol Exp Neurol; 2014 Sep; 73(9):837-45. PubMed ID: 25111021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis.
    Lee T; Li YR; Chesi A; Hart MP; Ramos D; Jethava N; Hosangadi D; Epstein J; Hodges B; Bonini NM; Gitler AD
    Neurology; 2011 Jun; 76(24):2062-5. PubMed ID: 21562248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations.
    Tradewell ML; Yu Z; Tibshirani M; Boulanger MC; Durham HD; Richard S
    Hum Mol Genet; 2012 Jan; 21(1):136-49. PubMed ID: 21965298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.